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Abstract
Traumatic brain injury (TBI) is the most common cause of death and disability in those aged under 40 years in the UK. Higher 
rates of morbidity and mortality are seen in low-income and middle-income countries making it a global health challenge. 
There has been a secular trend towards reduced incidence of severe TBI in the first world, driven by public health interven-
tions such as seatbelt legislation, helmet use, and workplace health and safety regulations. This has paralleled improved 
outcomes following TBI delivered in a large part by the widespread establishment of specialised neurointensive care. This 
update will focus on three key areas of advances in TBI management and research in moderate and severe TBI: refining neu-
rointensive care protocolized therapies, the recent evidence base for decompressive craniectomy and novel pharmacological 
therapies. In each section, we review the developing evidence base as well as exploring future trajectories of TBI research.
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Introduction
Traumatic brain injury (TBI) can be defined as the disrup-
tion in brain function, or other evidence of brain pathology, 
caused by an external physical force [1]. The yearly inci-
dence of TBI is estimated at 50 million cases worldwide; 
thus, approximately half of the global population will have 
an episode of TBI in their life [2]. In the UK, it is the most 
common cause of death and disability in those aged under 
40 years [3]. Moreover, even higher rates of morbidity and 
mortality are seen in low-income and middle-income coun-
tries [2]. Yearly, TBI costs the global economy approxi-
mately 400 billion US dollars, representing 0.5% of the gross 
world product [2].
TBI is a heterogeneous entity, reflecting several underly-
ing macroscopic modes of injury (e.g., extrinsic compression 
from mass lesion, contusion, diffuse axonal injury [DAI]) as 
well as a range of mechanisms by which neuronal injury 
can be inflicted (e.g., ‘classical’ ischaemia, apoptosis, mito-
chondrial dysfunction, cortical spreading depression [CSD], 
and microvascular thrombosis) in differing proportions with 
resultant varying clinical courses [4, 5]. Practically, the clini-
cal severity of TBI has long been stratified according to post-
resuscitation Glasgow Coma Scale scores into mild (GCS 
14–15), moderate (9–13), and severe (3–8) [6, 7]. Severe 
TBI has mortality rates of 30–40% and can cause significant 
physical, psychosocial, and social deficits in up to 60% of 
cases [8, 9].
There has been a secular trend towards reduced incidence 
of severe TBI in the first world, driven by public health 
interventions such as seatbelt legislation, helmet use, and 
workplace health and safety regulations. This has paralleled 
improved outcomes following TBI delivered in large part by 
the widespread establishment of specialised neurointensive 
care [10].
This update will focus on three key areas of advances in 
TBI management and research in moderate and severe TBI: 
refining neurointensive care protocolized therapies, estab-
lishing the evidence base for decompressive craniectomy, 
and developing novel pharmacological therapies.
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Refining neurocritical care and monitoring
The concept of primary and secondary injuries arose more 
than 25 years ago from a recognition that alongside the 
initial insult at the time of trauma, additional insults such 
as hypotension and hypoxia could supervene and exacer-
bate brain injury [11]. This simple concept has shaped TBI 
management in two ways: first, pre-hospital care protocols 
that ensure airway protection, systemic oxygenation, and 
adequate systemic perfusion and, second the use of moni-
toring and goal-directed therapy of neuronal physiology 
in the neurosciences critical care unit.
Intracranial pressure (ICP) monitoring
ICP is the most important goal-directed parameter in the 
clinical management of severe TBI (Fig. 1). Raised intracra-
nial pressure reduces cerebral perfusion (cerebral perfusion 
pressure = mean arterial pressure − ICP) risking ischaemia 
and, when severe and sustained, brain herniation. The Brain 
Trauma Foundation (BTF) has provided evidence-based 
guidelines (4th edition, 2016) that summarise the NCCU 
interventions available for controlling ICP in a staged fash-
ion, with a goal-directed target of 20–25 mmHg [12].
Despite the widespread use of ICP monitoring and 
acceptance in the TBI community, a recent randomized 
Fig. 1  Multi-modality monitor 
in neurocritical care—illustrat-
ing cerebral microdialysis, 
intracranial pressure and brain 
tissue oxygenation monitor-
ing. The microdialysis catheter 
allows sampling of the brain 
extracellular fluid by recovering 
molecules of interest that dif-
fuse across the catheter tip and 
are recovered within a microvial
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control trial of ICP monitoring (BEST: TRIP, 2012) 
was unable to show any benefit [13]. This trial has been 
severely criticized along two key lines: first, the trial was 
carried out in units that did not have previous experience 
of ICP monitoring (to allow ethical clinical equipoise) 
prior to the trial. Second, both groups of patients had 
aggressive ICP therapies irrespective. Therefore, the trial 
did not test the utility of ICP interventions but whether the 
numerical figure from the monitor provided benefit over 
‘blind’ management in units with no experience of using 
the monitors.
Brain multi‑modality monitoring
Brain multi-modality monitoring (MMM) is the use of mul-
tiple overlapping monitors to allow early detection of physi-
ological derangements and provide personalised targets for 
NCCU interventions (Fig. 1). Real-time data acquisition 
software such as ICM +, CNS Monitor and Bedmaster Ex 
allow both visualisation and analysis of these parameters at 
the bedside [14–16]. The definition of pathological targets 
for these monitors and determining the optimal method of 
correcting the physiological parameters has underpinned the 
advances in NCCU treatment of moderate and severe TBI. 
The two most widely used monitoring probes in addition to 
intracranial pressure monitors are brain tissue oxygenation 
and microdialysis monitors.
Brain tissue oxygenation monitoring
The use of brain tissue oxygen tension  (PbtO2) monitoring 
originally arose as a method for avoiding cerebral ischae-
mia during therapeutic hyperventilation for the control of 
ICP. The commonest method for monitoring  PbtO2 is using 
an invasive probe using a modified Clark electrode, with a 
typical pathological threshold of 20 mmHg (Fig. 1). In mul-
tivariate analysis of outcome,  PbtO2 has subsequently been 
shown to impact on outcome. This has led to prospective 
trials of  PbtO2 targeted therapy in addition to standard ICP 
driven care. A phase II trial (BOOST-II, Brain Tissue Oxy-
gen Monitoring and Management in Severe Traumatic Brain 
Injury) has demonstrated a significant reduction in hypoxia 
burden (74%) during hospitalization in the  PbtO2-targeted 
treatment group with no substantial safety issues. Depend-
ing on the study group, directed interventions were used for 
ICP management (if > 20 mmHg for > 5 min),  PbtO2 control 
(if < 20 mmHg for > 5 min) or both [17]. The third phase of 
the randomized study (BOOST-III) will evaluate the clinical 
efficacy of “a treatment protocol based on  PbtO2 monitoring 
compared to treatment based on ICP monitoring alone” and 
will enroll patients in the United States [18].
Cerebral microdialysis (CMD)
Cerebral microdialysis is an invasive monitor that allows 
sampling of the brain extracellular fluid for cerebral metabo-
lites through a semi-permeable blind-ended intraparenchy-
mal catheter (Fig. 1). It allows for direct measurement and 
trend profiling of several analytes of which the most impor-
tant are glucose, lactate, and pyruvate [allowing calculation 
of the lactate pyruvate ratio (LPR)] typically at hourly inter-
vals [19]. The Consensus Statement from the 2014 Inter-
national Microdialysis Forum, which thoroughly reviewed 
the literature on CMD in TBI, recommends a tiered clinical 
approach to CMD analytes [20]. This Consensus Statement 
identified LP ratio > 25 and low brain glucose < 0.8 mmol/L 
as pathological thresholds associated with unfavourable out-
comes and necessitating intervention [20–25].
While these parameters are well recognised as independ-
ent predictors of outcome over and above clinical parameters 
and ICP, there is no clearly defined intervention to correct 
a deranged LP ratio. This reflects the complexity of the 
underlying pathophysiology such that raised LP ratio can 
arise from a diverse range of pathologies including classi-
cal ischaemia, cortical spreading depression, mitochondrial 
dysfunction, microvascular collapse and diffusion limited 
hypoxia [26] (Fig. 2). Prospective protocols that address 
these issues sequentially are currently being assessed; how-
ever, no universally accepted treatment paradigm exists. 
Nonetheless, CMD has a key advantage over other monitor-
ing tools as it directly assesses the biochemical derange-
ments that occur following TBI, at the cellular level, pro-
viding a sensitive monitor of metabolic dysfunction, even 
if there are several pathological routes to this derangement.
Overall, there is still low-level evidence supporting asso-
ciation of CMD analyte levels with functional, neurophysi-
ological and tissue outcomes as highlighted by a recent sys-
tematic review on the topic [27]. Large prospective studies 
with a multimodal approach are warranted to better profile 
normal and pathologic values of CMD analytes, and to eval-
uate associations with patient and tissue outcomes.
Additional monitoring tools
Conceptually, cerebral blood flow (CBF) is an attractive 
metric to target within the NCCU; however, the practicali-
ties of measurement have limited its clinical utility. Thermal 
diffusion flowmetry (TDF) relies on repeatedly heating or 
cooling a probe and measuring the time to return to base-
line as a measure of the ability of cerebral blood flow to 
buffer temperature towards baseline core temperature. Sev-
eral monitors are commercially available; yet, they are all 
limited to variable baseline levels of quantified CBF and are 
not truly quantitative, making it difficult to target a patho-
logical threshold.
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Near infra-red spectroscopy (NIRS) can provide a met-
ric of oxygenated haemoglobin fraction, analogous to pulse 
oximetry, but is limited by the depth of penetration of the 
infra-red photons to superficial brain. The signal can also be 
contaminated by extracranial tissues (such as the temporalis 
muscle) making absolute quantification of the signal diffi-
cult. These two limitations limit the use of this technology 
to monitoring of the superficial frontal lobes.
Seizure prophylaxis
Continuous electroencephalography (EEG) is routinely used 
to monitor patients presenting with post-traumatic seizures 
(PTS), at increased risk of subclinical seizures or those who 
are pharmacologically paralyzed. The Brain Trauma Foun-
dation Guidelines suggest that in severe TBI, the rate of 
clinical PTS may be as high as 12%, while that of subclinical 
seizures may be as high as 20–25% [28]. There is additional 
interest in detecting cortical spreading depression as an 
additional injurious mechanism; however this is reliant on 
electrodes applied surgically directly to the cortical surface 
[5]. This has limited the ability to detect CSD systematically.
The BTF Guidelines reinstated the role of post-traumatic 
seizure prophylaxis with either phenytoin or levetiracetam 
within 7 days of injury (level IIA recommendation), with 
particular attention to adverse drug reactions. Benefits 
from PTS prophylaxis are both acute (limitation of neuro-
physiological derangements and prevention of herniation) 
and chronic (prevention of chronic epilepsy for which TBI 
patients are at higher risk) [28]. A meta-analysis from 2012 
showed no significant difference in post-traumatic seizure 
rates when comparing treatment with phenytoin and lev-
etiracetam in pooled studies [29]. Since then, another large 
prospective RCT found no difference in rates of early post-
traumatic seizures between the patient group treated with 
phenytoin and the other, with leviteracetam [30]. Long-term 
Fig. 2  Summary of the mechanisms of energy failure in traumatic 
brain injury that lead to increased brain lactate: pyruvate ratio (LP 
ratio). The conversion of lactate to pyruvate is an oxygen-independent 
step, whereas oxidative phosphorylation and the tricarboxylic acid 
cycle are oxygen-dependent. Of note, reduced cerebral blood flow 
and increased oxygen extraction fraction, which characterize classical 
ischemia, are typically not seen in microvascular ischemia. Mitochon-
drial dysfunction in the TBI context can arise from multiple patholog-
ical processes, often concurrently (most common shown). Ca2+ ion-
ized calcium, CBF cerebral blood flow, iNOS inducible nitric oxide 
synthase, LDH lactate dehydrogenase, NAD+ nicotinamide adenine 
dinucleotide (oxidised form), NADH nicotinamide adenine dinucleo-
tide (reduced form), NO nitric oxide, O2 oxygen, O2·−, superoxide 
radical, OH· hydroxyl radical, pO2 tissue oxygen saturation, ROS 
reactive oxygen species, TCA tricarboxylic acid cycle
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disadvantages from anti-convulsant use on neuropsychologi-
cal recovery in relation with timing and dosage are not yet 
fully understood and merit further prospective evaluation 
[28, 31].
Cerebral perfusion pressure and cerebrovascular 
autoregulation
The most recent BTF Guidelines recommend a universal 
CPP target of 60–70 mmHg in severe TBI patients requir-
ing ICP monitoring [28]. There has been a wide interest in 
how to personalise this target and targeting the endogenous 
autoregulatory range of an individual patient is conceptually 
appealing in that the cerebrovascular tree can regulate the 
downstream neural demands.
Cerebral autoregulation can be assessed using Pulse 
Reactivity index (PRx), the moving correlation coefficient 
between mean arterial pressure (MAP) and ICP (Fig. 3). 
The normal autoregulatory response to increased MAP is 
vasoconstriction to maintain constant cerebral blood flow, a 
reduction in arterial blood volume and, therefore, a reduction 
in ICP. Values above 0.25, whereby increases in MAP lead 
to an increased ICP, are indicative of impaired autoregula-
tion and correlate with mortality [32–34]. Conversely, nega-
tive values, whereby ICP does not increase with increas-
ing MAP, represent vasomotor reaction and prognosticate 
improved outcomes [35].
Steiner et al. in 2002 introduced the concept of CPPopt 
which represents the CPP at which PRx is minimised and the 
cerebral vasculature autoregulates most efficiently (Fig. 3). 
The CPPopt Guided Therapy Assessment of Target Effec-
tiveness (COGiTATE) study is an ongoing multi-center, 
phase II non-blinded RCT evaluating the safety and fea-
sibility of maintaining CPP at an individualized target in 
severe TBI patients recruited < 24 h from injury. This will 
provide important insight on the feasibility of individual-
ized autoregulation-oriented therapy concept in severe TBI 
patients.
Biomarkers
Sustained efforts have been made to identify biomarkers of 
the injury that results from TBI to detect ongoing injury, 
to stratify the need for monitoring and interventions and to 
provide prognostic information. Several biological compart-
ments have been assessed including serum, cerebrospinal 
fluid, cerebral microdialysate from brain extracellular fluid, 
and brain tissue. Biomarkers are currently not performed 
routinely outside of clinical research contexts. Noteworthy 
biomarkers in TBI include glia-related biomarkers (GFAP, 
S100B), neuron/axon-related biomarkers (neuron-specific 
enolase [NSE], neurofilament light polypeptide [NFL], ubiq-
uitin carboxy-terminal hydrolase [UCH-L1], tau, amyloid β, 
αII-Spectrin breakdown products among others) and other 
inflammation-related biomarkers (high mobility group box 
protein 1 [HMGB1], various cytokines and autoantibodies) 
[33, 34]. To date, only S100B is part of a consensus guide-
line pathway (by the Scandinavian Neurotrauma Committee) 
for stratification of mild TBI patients at presentation for CT 
imaging [36]. No guidelines regarding use of biomarkers in 
severe TBI exist.
Protein biomarkers with a shorter serum half-life (t1/2), 
e.g., S100B (t1/2 ~ 24 h) are likely more useful than proteins 
with a longer serum half-life, e.g., NSE (t1/2 ~ 48–72 h). A 
longer half-life offers a longer post-injury window for the 
detection of secondary neurological insults in severe TBI 
[37].
Therapeutic hypothermia
There are several plausible mechanisms by which hypother-
mia can mitigate the effects of TBI including reducing ICP, 
reducing the innate inflammatory response and reducing the 
cerebral metabolic rate. These need to be balanced against 
the risks of coagulopathy, immunosuppression, hypotension, 
pneumonia, renal impairment and decreased catecholamine 
responsiveness [28, 38]. Two large phase 3 randomized tri-
als have attempted to show the putative benefit of thera-
peutic hypothermia. The multi-center non-blinded RCT 
Eurotherm3235 (2015) is the largest trial on hypothermia 
for patients with intracranial hypertension (> 20 mmHg) 
after TBI. This study showed that therapeutic moderate 
hypothermia (32–35 °C) plus standard care to reduce ICP 
led to slightly increased mortality rates and unfavourable 
functional outcomes compared to those with standard care 
alone. Furthermore, an adverse association between hypo-
thermia and worsening multiple organ failure was noted [39, 
40]. A Cochrane Review (March 2016) on mild hypother-
mia in severe brain injury, which included 37 studies with 
3110 participants, demonstrated no high-quality evidence 
that hypothermia reduces mortality and morbidity in patients 
with severe TBI [41]. Despite this, hypothermia is routinely 
used in many units with two staged therapeutic targets, 35 °C 
and 33 °C.
More recently, the multi-center Prophylactic Hypother-
mia Trial to Lessen Traumatic Brain Injury—Randomized 
Clinical Trial (POLAR-RCT, 2018) evaluated outcomes of 
early, prophylactic, sustained hypothermia (33–35 °C), for 
at minimum 72 h and up to 7 days, in severe TBI patients. 
The intention-to-treat population included a total of 500 
patients with severe TBI randomized to either normother-
mia (n = 240) or early hypothermia (n = 260). The study did 
not show any benefit from early prophylactic hypothermia 
in neurological outcomes and mortality at 6 months when 
compared to normothermia. Intention-to-treat analysis dem-
onstrated increased rates of pneumonia in the hypothermia 
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group (55.0%) vs the normothermia group (51.3%) [42]. 
This study has been criticized for the use of severe hypother-
mia in patients prophylactically, even in those without raised 
ICP. In this group, the risks of hypothermia may exceed the 
putative benefits.
Future directions
The introduction of protocolized therapy for moder-
ate–severe TBI has undoubtedly improved outcomes for 
patients and provided a more consistent management. Never-
theless, the inability to demonstrate a benefit in randomized 
control trials for established interventions such as ICP moni-
toring and hypothermia is problematic for the field. When 
designing trials there is a balance between choosing specific 
subsets of patients who may benefit from an intervention 
against the need to recruit sufficient numbers of patients to 
pragmatically deliver a suitably powered trial. Certainly, 
the current evidence highlights that universally applying an 
intervention such as hypothermia without appropriate strati-
fication risks causing harm as much as any benefit.
Decompressive craniectomy
Decompressive craniectomy (DC) is a method of removing 
a substantial portion of the skull vault to reduce ICP and 
reduce the consequent deleterious sequelae (Fig. 4) [43]. 
RCT-based recommendations of trauma DC flap size in 
refractory raised ICP due to severe TBI suggest the use of 
12 × 15-cm flaps is associated with lower mortality (26% vs 
35%) and higher Extended Glasgow Outcome Scale (GOS-
E) scores when compared to smaller flap sizes [44]. DC can 
be classified as primary—after evacuation of a haematoma 
during the acute TBI phase and secondary—independently 
of haematoma evacuation for ICP control [43, 45].
The use of secondary DC in refractory elevated ICP 
after severe TBI was explored in the DECRA trial (recruit-
ment 2002–2010), which offered prophylactic DC (within 
72 h of TBI) in cases of diffuse (on CT) or severe (on GCS 
scoring) TBI [46]. 155 cases were randomized to surgi-
cal and control arms, where ICP was raised ≥ 20 mmHg 
for > 15 min within an hour period—despite first-tier medi-
cal treatment (i.e., excluding hypothermia and barbiturates 
use). Importantly, patients who had intracranial haema-
toma evacuation without primary DC, patients who had 
a hemi-DC were excluded and patients with bilaterally 
unreactive pupils were included (forming 27% of surgi-
cal arm patients vs 12% of the control group). Mortal-
ity rates at 6 months were similar at 19% in the surgery 
group and 18% medical group. Disability at 6 months in 
terms of RESCUE-ICP defined (see below) “unfavour-
able” outcomes were 37% in the surgical group vs 23% 
in the medical arm, whereas “favourable” were 44% in 
the surgical arm compared to 59% in the control cohort. 
After post hoc adjustment for baseline pupil reactivity, 
functional differences between the two arms were found 
to be no longer statistically significant [46]. Similar to 
the POLAR and Eurotherm3235 studies, it appears that 
unstratified prophylactic use of this intervention does not 
confer any benefit to patients.
RESCUE-ICP (recruitment 2004–2014) was an interna-
tional prospective RCT comparing DC (bifrontal or large 
unilateral) plus medical management with medical man-
agement alone as therapy for TBI patients with severe, sus-
tained and refractory intracranial hypertension [47]. 408 
patients were included and randomized when all medical 
management, other than barbiturate coma, were exhausted 
and ICP remained elevated > 25 mmHg for 1–12 h. Impor-
tantly, patients with fixed bilateral pupils, un-survivable 
injury, bleeding diathesis or those treated with primary DC 
were excluded. At 6 months after randomization, secondary 
DC resulted in lower mortality rates (26.9% vs 48.9% in 
the medical group). Functional outcomes at 6 months were 
measured via GOS-E [48] (Fig. 5). Outcomes graded as 
upper severe disability or better were categorised as “favour-
able” and were seen in 42.8% of surgical cases vs 34.6% of 
medical cases. “Unfavourable” outcomes (lower severe dis-
ability and vegetative state) were 30.4% of surgical cases vs 
16.5% of medical cases (47). Of note, incidence of persistent 
vegetative state was 8.5% in the surgical group compared to 
2.1% in the medical group. RESCUE-ICP demonstrated that 
as last tier therapy for raised ICP, DC can reduce mortality, 
though at a cost of increased severe disability and persistent 
vegetative state [46, 47, 49]. There is no simple answer as 
to when DC should be used in severe TBI with medically 
refractory ICP; however, RESCUE-ICP provided some clear 
data on the expected outcomes in this context informing the, 
often complex, discussions with family when this interven-
tion is considered. This study was published after release of 
the 4th edition of the BTF guidelines.
There is relative paucity in data regarding the use primary 
DC in TBI, which is more frequently implemented than 
secondary DC [49, 50]. The currently recruiting RESCUE-
ASDH trial is randomizing TBI patients undergoing evacu-
ation of acute subdural haematomas (ASDH) to craniotomy 
vs with primary DC [49, 51].
Fig. 3  Bar chart of RESCUE-ICP trial outcomes at 6  months [47]. 
Outcomes are displayed using the Extended Glasgow Outcome Scale 
(eGOS) on the horizontal axis. eGOS at 6 months represents the pri-
mary outcome measure of this trial. The percentage of patients falling 
within the respective outcome category is displayed in the figure table 
and illustrated in the corresponding graph. “Favourable” outcomes 
were defined as upper severe disability or better in the RESCUE-ICP 
trial. “Unfavourable” outcomes comprise of lower severe disability 
and vegetative state
◂
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Future directions
One consequence of DC that is undergoing increasing inter-
est, is the need for cranioplasty (replacement of the bony 
defect with an artificial plate). There is no consensus on the 
timing of cranioplasty, the cranioplasty material (e.g., tita-
nium, polyethylene, methyl methacrylate, and hydroxyapa-
tite) or the use of autologous bone [49, 52]. It is hoped 
that initiatives such as the NIHR Global Health Research 
Group on Neurotrauma and the Collaborative European 
NeuroTrauma Effectiveness Research in Traumatic Brain 
Injury (CENTER-TBI) shed light on these questions across 
resource settings [53, 54].
Pharmacological therapies for TBI
Despite several decades of successful pre-clinical studies 
that have developed promising neuroprotective therapies, 
none have translated into the clinical arena. Unfortunately, 
there is still no proven curative pharmacotherapy for mod-
erate-to-severe TBI nor pharmacotherapy with unequivocal 
benefit in functional outcomes. This universal failure has 
Fig. 4  a Bifrontal decompres-
sive craniectomy with the dotted 
line on the dura representing 
durotomy site and the red line 
illustrating an area of falxotomy. 
b Decompressive hemi-
craniectomy with the dotted line 
representing durotomy incision. 
Adapted with permission from 
Timofeev et al. (2012) [43]
Fig. 5  Bar chart of RESCUE-ICP trial outcomes at 6 months (47). 
Outcomes are displayed using the Extended Glasgow Outcome Scale 
(eGOS) on the horizontal axis. eGOS at 6 months represents the pri-
mary outcome measure of this trial. The percentage of patients falling 
within the respective outcome category is displayed in the figure table 
and illustrated in the corresponding graph. “Favourable” outcomes 
were defined as upper severe disability or better in the RESCUE-ICP 
trial. “Unfavourable” outcomes comprise of lower severe disability 
and vegetative state
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highlighted the biological differences between human and 
rodent TBI, the lack of investment into mechanistic human 
TBI studies, the need to accurately define the population 
who may benefit and the importance of pharmacokinetic 
studies in humans.
Corticosteroids
The first large scale pharmacological trial in TBI was the 
MRC-funded (Medical Research Council, United Kingdom) 
Corticosteroid Randomisation after Significant Head Injury 
study (MRC CRASH, 2004), which randomized moderate-
to-severe TBI patients to a 48-h infusion of high dose corti-
costeroids (methylprednisolone) or placebo. 10,008 patients 
were recruited from 1999–2004 from 239 hospitals in 49 
countries. The trial primary outcome was 2-week mortality, 
which was higher in the treatment group (21.1%) than in 
the placebo group (17.9%). At 6 months of follow-up, there 
were 173 excess deaths in the treatment arm (1248 vs 1075). 
The known complications of corticosteroids such as hyper-
glycaemia and immunosuppression were not systematically 
treated in this study [55].
Progesterone
With the failure of corticosteroids in TBI, pre-clinical ani-
mal studies focussed on the early administration of pro-
gesterone, a potent neurosteroid synthesized in the central 
nervous system, and showed that it reduced neuronal loss, 
cerebral oedema, and behavioral deficits after experimental 
TBI. Progesterone has then been investigated by large dou-
ble-blind placebo-controlled -phase III multi-center RCTs 
(SYNAPSE and PROTECT III published in 2014) without 
demonstrating benefit in patient mortality and functional 
outcomes, halting enthusiasm generated by two precedent 
single-center clinical studies [56–59].
Erythropoietin
Erythropoietin (EPO) is a glycoprotein regulating haema-
topoiesis in the bone marrow which is naturally produced 
in the kidneys following hypoxic stimulation. Animal stud-
ies have demonstrated that EPO can neutralize the neuronal 
apoptotic program, reduce the inflammatory response and 
act as a neurotrophic factor, thus it is hypothesized to allevi-
ate the impact of secondary brain injury in TBI [60]. EPO 
use in severe TBI has been controversial owing to select 
studies showing functional outcome benefits and others 
finding no significant outcome difference [61, 62]. A meta-
analysis of 6 RCTs with 1041 patients (up to January 2017) 
looking at outcomes of EPO-treated patients vs untreated 
patients following acute (moderate-to-severe) TBI showed 
that EPO significantly reduced mortality but did not reduce 
rates of poor functional outcome. There were no significant 
differences in complication rates including deep venous 
thrombosis between the treatment groups [63]. Further well-
designed prospective work is required to clarify these find-
ings and determine optimum dosage and treatment timing.
Amantadine
Amantadine hydrochloride works as a N-methyl-d-aspartate 
(NMDA) antagonist and indirect dopamine agonist [64]. A 
prospective multi-center double-blind RCT examined aman-
tadine administration vs placebo over 4 weeks followed by 
2 weeks in which treatment was discontinued in 184 adult 
patients who were in a vegetative or minimally conscious 
state 4–16 weeks after TBI and who were receiving inpa-
tient rehabilitation. The study concluded that amantadine 
accelerated the pace of functional recovery as measured by 
the Disability Rating Scale (DRS) during the active 4-week 
treatment without significant difference in the incidence of 
serious adverse events in patients with post-traumatic dis-
orders of consciousness [65]. Another small single-center 
double-blind RCT evaluating amantadine vs placebo given 
for 6 weeks in 40 severe TBI patients did not show any sig-
nificant effect on patient mortality and functional outcomes 
at 6 months [66]. A multi-center double-blind RCT evalu-
ated the efficacy of amantadine vs placebo administered for 
60 days on cognitive function in 119 patients with chronic 
TBI (> 6-month post-injury). This study failed to show bene-
fits from amantadine administration in chronic TBI and even 
suggested that amantadine may hinder cognitive processing 
within first 28 days of use [67].
Tranexamic acid
Tranexamic acid (TXA), a synthetic derivative of the amino 
acid lysine, is an antifibrinolytic agent used to reduce active 
bleeding [68]. It works by reversible blockade of the lysine 
sites on plasminogen [69]. In about 30% of TBI patients, 
laboratory markers for coagulation are deranged [70]. Fur-
thermore, peri-haemorrhage damage and oedema within the 
brain is associated with worse neurological outcomes [71].
In the trauma setting (excluding intracranial bleeds), TXA 
administration has been associated with decreased mortal-
ity particularly if used early, elucidated by the CRASH-2 
trial [72]. This trial randomized 20,211 adult trauma patients 
with, or at risk of, significant bleeding randomized within 
8 h of injury to either TXA or matching placebo [72]. Sub-
sequently, TXA’s cost-effectiveness in trauma protocols has 
earned it a spot in the World Health Organization (WHO) 
List of Essential Medicines [68].
A nested study within CRASH-2 examining the subgroup 
of trauma patients with extracranial bleeding and TBI with 
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abnormal CT brain findings found a non-significant trend 
towards reduction in hemorrhage growth, ischaemic lesions, 
and mortality with TXA administration [73].
These findings have formed the foundation for the 
Tranexamic Acid for Significant Traumatic Brain Injury 
(CRASH-3) trial, a RCT aimed at evaluating whether the 
benefits of TXA are transferable to TBI patients with trau-
matic intracranial bleeding [68], currently ongoing and 
eagerly anticipated.
Citicoline
Citicoline is a cholinergic agent which can increase forma-
tion of ATP—hypothesized to promote the functioning of 
cell-membrane ATP-dependent pumps and thus increase 
cell-membrane integrity and decrease cellular oedema [74]. 
In this way, it was considered a potential therapeutic agent 
against parts of secondary brain injury process. The multi-
center double-blind randomized phase III Citicoline Brain 
Injury Treatment Trial (COBRIT) though failed to dem-
onstrate improvement in functional and cognitive status at 
90-day post-injury in moderate-to-severe and mild compli-
cated TBI patients from the use of citicoline vs placebo [75].
Anti‑inflammatory therapies
Recombinant interleukin-1 receptor antagonist (rIL1ra) has 
demonstrated putative benefit in a range of neuronal patholo-
gies by inhibition of the IL1 receptor mediated inflammatory 
cascade [76, 77]. In TBI it has been shown to be safe and 
modify the acute neuroinflammatory response in a phase II 
single-center RCT [78]. A dose ranging study to optimise 
both the dose and timing of administration is currently in 
progress [79].
Conclusions
TBI is a major global health challenge and priority. There 
are several promising lines of research directed towards 
optimising neurointensive care protocols, developing an 
evidence base for surgical intervention, and translating 
promising neuroprotective pharmacotherapies into applica-
tion to human pathology. The importance of personalised 
medicine and combinatorial therapy in the field of TBI can-
not be overstated given the heterogeneity of the pathology 
such that a single intervention cannot address every patho-
logical mechanism at play. This is at odds with conventional 
randomized control trial methodology and may underpin the 
large number of failures of RCTs to demonstrate any benefit 
in this pathology.
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